Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1998-07-29
2000-11-28
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
514218, 514221, 514247, 514248, 514249, 51425305, 514258, 514307, 540470, 540472, 540556, 540575, 540577, 540579, 540597, 544235, 544238, 544242, 544253, 544282, 544316, 544319, 544349, 544351, 544363, A61K 3155, A61K 31495, C07D24500, C07D49100, C07D40100, C07D23900, C07D48700, C07D23970, C07D23902
Patent
active
061536083
DESCRIPTION:
BRIEF SUMMARY
TECHNICAL FIELD
The present invention relates to an isoquinoline derivative having cerebral vasospasm-inhibiting activity and, thus, finding application as a medicine.
BACKGROUND ART
Cerebrovascular disease can be groupified into a hemorrhagic group and an ischemic group. The hemorrhagic group typically comprises subarachnoid hemorrhage arising from aneurysmal rupture, hypertensive cerebral hemorrhage, and head trauma. Subarachnoid hemorrhage entails a delayed vasospasm of the major cerebral arteries and may lead to vascular constriction disorders and sometimes to death. The ischemic group is represented by cerebral infarction and transient ischemic attack (TIA). The vascular disorder and neuronal injury caused by infarction or hemorrhage may lead to dyskinesia such as numbness or motor paralysis of the limbs and neurologic and mental dysfunctions in the acute through chronic stage, with disturbance of consciousness and death ensuing in severe cases.
For the treatment of such cerebrovascular diseases, antithrombotics and enhancers of cerebral circulation and metabolism have been used to this day. However, few drugs are available which inhibit this fatal cerebral vasospasm or the neuronal injury leading to dementia and there exists a pressing need for an effective therapeutic agent.
By way of illustration, as subarachnoid hemorrhage takes place, narrowing of the vascular lumen persisting for several weeks is induced in the major cerebral arteries in 4.about.5 days following the bleeding event. This phenomenon is known as cerebral vasospasm and once the ultimate ischemia triggers the onset of neurological symptoms, the functional prognosis and, at times, even the vital prognosis of the case are seriously influenced.
As the therapeutic drug for cerebral vasospasm subsequent to subarachnoid hemorrhage, fasudil [hexahydro-1-(5-isoquinolinylsulfonyl)-1H-1,4-diazepine] hydrochloride is the only drug that is used clinically today (Japanese Kokai Tokkyo Koho S61-227581).
Aside from the above drug, it is known that compounds having an isoquinoline ring substituted by cyclic aminosulfonyl in its 5-position are useful as cerebrovascular drugs (vasodilators, enhancers of cerebral circulation and metabolism, antianginal drugs, prophylactic and therapeutic drugs for cerebrovascular or cardiovascular thrombosis, and prophylactic and therapeutic drugs for hypertension) [Japanese Kokai Tokkyo Koho S57-156463, S58-121279, and S61-227581].
Not known, however, is a compound such that its isoquinoline skeleton has been substituted by a cyclic aminosulfonyl group in its 5-positon and further substituted in its 4-position.
DISCLOSURE OF THE INVENTION
The object of the invention is to provide a compound which is structurally novel, only sparingly toxic, and superior to any known drug as a prophylactic or therapeutic drug for cerebrovascular diseases, particularly as a cerebral vasospasm inhibitor.
To accomplish the above object, the inventors of the present invention synthesized and screened a large number of structurally new compounds and found that a compound of the following general formula [I] has very satisfactory cerebral vasospasm-reversing activity. The present invention has been developed on the basis of the above finding.
The present invention, therefore, is concerned with a compound of the following general formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a medicinal composition comprising it as an active ingredient, ##STR2## wherein R.sup.1 represents alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, or halogen; substituted, which cyclic amino group may be bridged between two carbon atoms in optional positions.
In chemical structure, the compound of the invention is characterized in that the 4-position of an isoquinoline skeleton is substituted by a substituent selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxy, cyano, and halogen.
The present invention is now described in detail.
The "alkyl" in the context of the present invention includes straight-
REFERENCES:
patent: 4456757 (1984-06-01), Hidaka et al.
patent: 4634770 (1987-01-01), Hidaka et al.
patent: 4678783 (1987-07-01), Hidaka et al.
Hidaka Hiroyoshi
Matsuura Akira
Matsuzaki Takushi
Nippon Shinyaku Co. Ltd.
Schroeder Ben
Shah Mukund J.
LandOfFree
Isoquinoline derivatives and drugs does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Isoquinoline derivatives and drugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoquinoline derivatives and drugs will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1726029